Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Change in Cash (2024 - 2026)

Beta Bionics recorded quarterly Change in Cash of -$1.4 million in Q1 2026, up 80.17% quarter-over-quarter from -$6.9 million in Q4 2025, and down 111.4% year-over-year from $12.0 million in Q1 2025.

Beta Bionics' Change in Cash history runs 3 years deep, the most recent figure standing at -$1.4 million for Q1 2026.

  • In Q1 2026, Change in Cash fell 111.4% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at -$12.2 million (down 160.09% YoY), while the FY2025 annual figure was $1.1 million, down 70.41% from the prior year.
  • Change in Cash came in at -$1.4 million for Q1 2026 at Beta Bionics, up from -$6.9 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $13.0 million in Q4 2024 to a low of -$9.0 million in Q2 2024.
  • A 3-year average of $404444.4 and a median of -$1.4 million in 2026 frame the typical range for Change in Cash.
  • On a YoY basis, Change in Cash climbed as much as 367.51% in 2025 and fell as far as 153.35% in 2025.
  • Beta Bionics' Change in Cash stood at $13.0 million in 2024, then sank by 153.35% to -$6.9 million in 2025, then jumped by 80.17% to -$1.4 million in 2026.
  • According to Business Quant data, Change in Cash over the past three periods registered -$1.4 million, -$6.9 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -1.72 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -1.13 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -136.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -504.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -492.00 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 199.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -2.23 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 15.90 Mn
10 Beta Bionics 572.34 Mn 542.03 Mn 16.44 Mn -1.37 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -1.37 Mn
Dec 31, 2025 -6.91 Mn
Sep 30, 2025 3.41 Mn
Jun 30, 2025 -7.38 Mn
Mar 31, 2025 12.02 Mn
Dec 31, 2024 12.95 Mn
Sep 30, 2024 4.45 Mn
Jun 30, 2024 -9.04 Mn
Mar 31, 2024 -4.49 Mn